Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
December 7th 2023Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.
Read More
Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors
September 19th 2023Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.
Read More
Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC
May 4th 2023Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.
Read More
Dr Graff on Data From HER2CLIMB Exploratory Analysis in HER2+ Breast Cancer With Brain Metastases
April 6th 2023Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.
Read More
Future Directions in Care for HER2+ Breast Cancer
Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Read More
Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer
Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.
Read More
Novel Treatment Strategies for HER2-Low Breast Cancer
Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.
Read More
Establishing the Paradigm of HER2-Low Breast Cancer
Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.
Read More
Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer
Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.
Read More
HER2+ mBC: Practical Selection and Sequencing of Therapy
Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.
Read More